Anti-Scarring Effect of Lactoferrin Derivative

Cellastra became interested in lactoferrin and subpeptides thereof because of published studies. Swedish scientists discovered that certain polypeptides derived from human lactoferrin have potent anti-scarring properties. The most potent of these was PXL01 (ensereptide), a lactoferrin subpeptide of 25 amino acids. Ensereptide had higher anti-inflammatory, anti-scarring and anti-bacterial properties, than its parent molecule. PXL01 was found to disrupt excessive scar and adhesion formation in preclinical and clinical proof of concept studies, as summarized in the studies listed below. Furthermore, this was achieved with no evidence of a negative impact on the
normal wound healing process or with other safety concerns, such as tendon fragility.

Cellastra is developing the technology to allow for continuous production of an ensereptide
fusion protein at wound sites, negating the effects of peptide metabolism and short half-life in
vivo.